TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has entered into a binding Letter of Intent (LOI) with Allucent, a global contract research organization with extensive experience supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid ...

Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting DemyelinationTORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has entered into a binding Letter ...

Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Quantum’s strong balance sheet and overall progre ...

Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its audited financial and operational results for the fourt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Highlights advancement of first-in-class neuroprotective candidate targeting demyelinationTORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 clinical trial evaluating Lucid-21-302 (Lucid-MS), an inves ...

Core Viewpoint - Quantum BioPharma Ltd. announced the publication of a clinical trial demonstrating that its dietary supplement 'unbuzzd' significantly accelerates alcohol metabolism, reduces blood alcohol concentration (BAC), and alleviates symptoms of intoxication and hangover [1][7]. Clinical Trial Findings - The clinical trial was a double-blind, randomized, placebo-controlled study involving healthy participants aged 21 to 43, who consumed alcohol to achieve a BAC between 0.07% and 0.11% before taking either unbuzzd or a placebo [2]. - unbuzzd reduced BAC by more than 40% faster within the first 30 minutes compared to placebo, with continued acceleration observed over a four-hour period [5]. - Participants reported significant improvements in alertness within 30 minutes of consuming unbuzzd, outperforming placebo results [6]. - The supplement stabilized heart rate and blood pressure, which are typically elevated during alcohol intoxication, with these results being statistically significant [6]. - Participants experienced a statistically significant reduction in hangover symptoms, including a 67% reduction in headache severity at four and eight hours post-consumption [6]. Product Information - unbuzzd is a dietary supplement developed by a team of scientists at Quantum BioPharma, comprising a proprietary blend of vitamins and supplements [1][9]. - The product is available for purchase through its website and on Amazon, with various packaging options [10]. - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which markets unbuzzd, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will drop to 3% [12].

Core Viewpoint - A class action lawsuit has been filed against Quantum Biopharma Ltd. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by February 23, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that Quantum and certain officers and/or directors engaged in securities fraud [1]. - Defendants, including CIBC World Markets and Royal Bank of Canada, are accused of placing thousands of spoofed sell orders to create a false impression of Quantum's stock price decline [1]. - These manipulative orders allegedly deceived investors into selling their shares at artificially low prices, allowing the Defendants to purchase shares at depressed levels for profit [1]. Group 2: Legal Representation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is representing the affected investors [1]. - The firm has a long history of fighting for victims of securities fraud and has recovered numerous multimillion-dollar damages awards [1].

Core Viewpoint - Quantum Biopharma, Ltd. is facing a class action lawsuit for allegedly misleading investors during the Class Period from January 6, 2021, to October 15, 2025, with claims of stock price manipulation [1][2]. Group 1: Class Action Details - Investors who purchased Quantum securities during the specified Class Period have until February 23, 2026, to file a lead plaintiff motion [1]. - The lawsuit is being led by the Portnoy Law Firm, which offers complimentary case evaluations for affected investors [2]. Group 2: Allegations Against Defendants - The Complaint alleges that Defendants engaged in thousands of spoofed sell orders to create a false impression of a declining stock price for Quantum [2]. - These manipulative orders were intended to deceive investors into selling their shares at artificially low prices [2]. - Following the price decline, Defendants allegedly bought Quantum shares at these depressed levels, allowing them to profit from the scheme [2]. - As a result of these actions, investors were improperly induced to sell their shares at artificially depressed prices [2].

Core Viewpoint - A class action lawsuit has been filed against Quantum Biopharma Ltd. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders of Quantum Biopharma Ltd. and is being handled by Pomerantz LLP [1]. - Investors have until February 23, 2026, to request to be appointed as Lead Plaintiff if they purchased Quantum securities during the Class Period [2]. Group 2: Allegations Against Defendants - The complaint alleges that several financial institutions, including CIBC World Markets and RBC Capital Markets, engaged in manipulative trading practices by placing thousands of spoofed sell orders [4]. - These spoofed orders created a false impression of Quantum's stock price declining, leading other investors to sell their shares at artificially low prices [4]. - After driving the stock price down, the defendants purchased shares at these depressed levels to profit from the manipulation [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud [5]. - The firm has a track record of recovering multimillion-dollar damages for class members over its 85-year history [5].